Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma.
about
How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?CholangiocarcinomaCholangiocarcinoma: Current Knowledge and New DevelopmentsManagement of perihilar cholangiocarcinoma in the era of multimodal therapyAngiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma.Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitisCancer surveillance in patients with primary sclerosing cholangitis.Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management.Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing CholangitisMalignancies in Primary Sclerosing Cholangitis--A Continuing ThreatAsia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma.Novel diagnostic and prognostic biomarkers in biliary tract cancer.The treatment of cholangiocarcinoma: a hepatologist's perspective.Diagnostic and prognostic serum marker of cholangiocarcinoma (Review)Screening for malignancy in primary sclerosing cholangitis (PSC).Greater Biosynthetic Liver Dysfunction in Primary Sclerosing Cholangitis Suggests Co-existent or Impending Cholangiocarcinoma.An update on cancer risk and surveillance in primary sclerosing cholangitis.Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma.Predictors for the development of cholangiocarcinoma and hepatocellular carcinoma: in search for the most accurate biomarker.A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin.Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis.Recent developments in the management of idiopathic cholestatic liver diseaseIncreased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma.CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma.[Diagnostics and treatment of cholangiocellular carcinoma].Plasma orosomucoid 2 as a potential risk marker of cholangiocarcinoma.Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma.Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis.Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures.Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinomaSerum Level of Ca 19-9 Increases Ability of IgG4 Test to Distinguish Patients with Autoimmune Pancreatitis from Those with Pancreatic Carcinoma
P2860
Q26782878-7019DD60-F9BB-4295-BDE2-7986F023B45DQ27001694-4EAEB80B-831D-405C-9F30-40146079347CQ28076098-DB5CAA59-07D3-4457-A61D-57F096CBAA27Q28273788-A479AC5A-206A-46CD-B282-0C70B09A85E8Q33605089-E2F3DC08-8C4C-49DA-BBBC-345CE05FF6CEQ35146460-75D5970B-1D02-48AA-B78E-64D72FD0F596Q35490961-CDE21222-0221-47E1-B13A-F2F2432E380BQ36199767-22F111AD-A36D-4592-81C5-9181943CF7F2Q36805289-6FC91470-3364-4724-BD02-B0FBA8831E85Q37082378-09473371-C892-4FF7-B2E4-450B74246BD2Q38076736-B319F167-C77A-4303-A8F1-F9CAECB11552Q38131056-FC4BD683-C9DD-4C0B-9602-1C9F2F062345Q38245695-41F551E4-0632-4315-B31B-0685029DF7E6Q38272979-5CB2567D-FAE2-4BA4-9790-640BEBEFD9F8Q38383074-B89CE0BE-44A3-44F6-83B1-6F424482DEFEQ38798747-48A0B525-E101-48D9-A479-3D423C2B9F67Q39060326-0B17CAD7-7895-4DEE-94BD-640360C44CC7Q40193200-68D57018-902D-44F2-8734-B24D276A7302Q40623765-483B88C3-8B1F-4C4E-8FFE-51CDC2213094Q41303036-B2FF893C-8D43-4021-A342-FB4ADB6338E7Q41542251-A715C4F2-E25B-43A3-BDE3-E7807AE062E0Q42358514-07834462-E15A-46C0-BAD4-C2D12D711E92Q42406650-8E0DF471-366D-4853-925B-E3899FA546A7Q44096896-ABF59785-D1E3-4317-BA72-DA4D211B82B3Q46325969-861D8B17-1326-47AB-AA59-13EC2714EB36Q51073522-67AB92CA-5EAA-402D-8607-C9F3BEB32E2AQ51344472-F2785F47-EC9C-485A-9197-D2F639BDE667Q52972733-A11D747D-C142-42B6-ABE5-9217D0DA17D3Q54113632-9069B1B1-3955-4CC2-AB1E-86811AC227D8Q54313456-3A74286E-5425-467B-A37C-F75424098D76Q57114361-06FF9C5D-C9C0-4992-9640-99A075B7F6A9Q58376599-1254C922-22F0-4634-96EF-5D317DF4EFAF
P2860
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Many patients with primary scl ...... o not have cholangiocarcinoma.
@en
Many patients with primary scl ...... o not have cholangiocarcinoma.
@nl
type
label
Many patients with primary scl ...... o not have cholangiocarcinoma.
@en
Many patients with primary scl ...... o not have cholangiocarcinoma.
@nl
prefLabel
Many patients with primary scl ...... o not have cholangiocarcinoma.
@en
Many patients with primary scl ...... o not have cholangiocarcinoma.
@nl
P2093
P1476
Many patients with primary scl ...... o not have cholangiocarcinoma.
@en
P2093
Amy K Saenger
Emmanouil Sinakos
Jill Keach
Keith D Lindor
P304
P356
10.1016/J.CGH.2011.02.007
P407
P577
2011-02-17T00:00:00Z